Quidelortho Corp
F:QL1A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Quidelortho Corp
F:QL1A
|
US |
|
G
|
Guangdong Hongjing Optoelectronic Technology Inc
SZSE:301479
|
CN |
|
Narasaki Sangyo Co Ltd
TSE:8085
|
JP |
|
Z
|
Zapf Creation AG
XMUN:ZPF
|
DE |
|
S
|
Sheela Foam Ltd
BSE:540203
|
IN |
|
Amana inc
TSE:2402
|
JP |
|
Vistra Corp
NYSE:VST
|
US |
|
Ivanhoe Mines Ltd
TSX:IVN
|
CA |
|
Otto Energy Ltd
ASX:OEL
|
AU |
|
D
|
Daiichi Commodities Co Ltd
TSE:8746
|
JP |
Quidelortho Corp
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream.
The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream.
The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
Revenue: QuidelOrtho reported Q4 revenue of $724 million and full-year revenue of $2.73 billion, achieving its 2025 financial guidance.
Growth Drivers: Strong growth in Labs (7% in Q4, 6% for the year) and positive performance in Triage and Immunohematology offset declines in COVID-related and Donor Screening revenues.
Margins: Adjusted EBITDA margin reached 22% for the year, improving by 240 basis points over 2024, with ongoing cost savings initiatives delivering $140 million.
Cash Flow: Free cash flow conversion was below the target, mainly due to timing issues, but management reiterated progress and expects improvement to about 30% of EBITDA in 2026.
2026 Guidance: Revenue is expected between $2.7 billion and $2.9 billion, EBITDA of $630–670 million, flat gross margins, and adjusted EPS between $2 and $2.42.
Product Pipeline: R&D progress included FDA clearances for new assays and launches of informatics solutions, with multiple new product/platform launches planned for 2026.
China Exposure: Management reiterated low single-digit growth outlook for China and noted potential VBP impact would be limited to 0.5–1% of company revenue if applicable.
